03/04/2015 - 13:00 SAN FRANCISCO – An investigational topical sebum inhibitor met its primary endpoints in a phase IIa trial, significantly reducing inflammatory and n... More » Visit websiteField of Interest: DermatologyCategories: FPN || NewsFPN || DermatologyIMN || NewsIMN || DermatologyPED || NewsPED || DermatologySAN || Clinical NewsNews Feed: Internal Medicine News - Dermatology
